Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827058 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL6921164 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL6827161 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL6220086 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL8457213 | 0.91 | SLC10A2 (0.84) | SLC10A2 | |
| SCHEMBL6222198 | 0.91 | SLC10A2 (0.84) | SLC10A2 | |
| SCHEMBL6224734 | 0.88 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL6224730 | 0.88 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL6222284 | 0.87 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL1361679 | 0.87 | SLC10A2 (0.78) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555950-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SATIOGEN PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10251880-B2 | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SATIOGEN PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20160220577-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160220577-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20150087642-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150087642-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-6740663-B2 | ANTIHYPERLIPIDEMIC AGENTS | G.D. SEARLE, LLC | 2004-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251880-B2 | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SLC10A2, GPR119, GPBAR1 | SLC10A2 1/4885 |
| US-20150087642-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SLC10A2, GPR119, GPBAR1 | SLC10A2 1/4885 |
| US-10555950-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20160220577-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.